Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
A convergence of DFT techniques and the proliferation of in-silicon monitors can flag potential failures before they occur.
Follow Boston.com on Instagram (Opens in a New Tab) Follow Boston.com on Twitter (Opens in a New Tab) Like Boston.com on Facebook (Opens in a New Tab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results